Abstract

LSUMC-S has been a member of SWOG since 1982 and has had funding since 1993. After a period of time with relatively low accrual to protocols, accrual has recently markedly increased and currently is about 180/year and ranks within the top six institutions. LSUMC-S accounts for nearly 12 percent of all minority patients accrued to SWOG studies. Forty-seven percent of all patients placed on SWOG protocols from LSUMC-S are minority. LSUMC-S has four primary sites for patient accrual to studies. These include the University Hospital, the Overton Brooks VAMC, the Willis Knighton Medical Center and the E. A. Conway Hospital. Three CGOP sites are present--St. Francis Hospital, Monroe, Louisiana; Highland Hospital, Shreveport and Baptist Medical Center in New Orleans, Louisiana.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA058658-06
Application #
2450040
Study Section
Subcommittee G - Education (NCI)
Program Officer
Kaplan, Richard S
Project Start
1993-04-01
Project End
2002-12-31
Budget Start
1998-03-30
Budget End
1998-12-31
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
Louisiana State University Hsc Shreveport
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Shreveport
State
LA
Country
United States
Zip Code
71103

  Publications

Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13
Stiff, Patrick J; Unger, Joseph M; Cook, James R et al. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369:1681-90
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Petersdorf, Stephen H; Kopecky, Kenneth J; Slovak, Marilyn et al. (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121:4854-60
Berglund, Ryan K; Tangen, Catherine M; Powell, Isaac J et al. (2012) Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology 79:633-7

Showing the most recent 10 out of 92 publications